Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STW5-II in mild to moderate ulcerative colitis
NCT02246686Phase 2Terminated
- Sponsor
- Bayer
- Start
- Nov 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ulcerative colitis (UC) comparing STW5-II with Placebo (2 arms). Primary endpoints: Proportion of patients being in remission at final visit at 12 weeks, Change of endoscopic index (EI) at 12 weeks and 13 more. Started Nov 2014; status: terminated.
02
Drugs
STW 5-II
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02246686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02246686.